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Abstract 
Background: Vibration-controlled transient elastography (VCTE) estimates liver stiffness measurement 
(LSM) and controlled attenuation parameter (CAP) which are noninvasive assessments of hepatic 
fibrosis and steatosis respectively.  However, prior VCTE studies reported high failure rate in patients 
with non-alcoholic fatty liver disease (NAFLD).   
Aim: To examine the performance characteristics of Fibroscan 502 Touch with two probes, medium 
(M+) and extra-large (XL+), in patients with NAFLD in a multicenter setting.  
Methods: A total of 1696 exams were attempted in 992 patients (BMI: 33.6 ± 6.5 kg/m
2
) with 
histologically confirmed NAFLD. Simultaneous assessment of LSM and CAP was performed using 
Fibroscan 502 Touch with an automatic probe selection tool. Testing was conducted twice in patients by 
either a single operator (88%) or two operators (12%). Failure was defined as the inability to obtain a 
valid examination.  An examination was considered unreliable if LSM IQR/median was >30%. Significant 
disagreement between two readings was defined as greater than >95% limits of agreement between 
two readings.  
Results: A total of 1641 examinations yielded valid results with a failure rate of 3.2% (55/1696).  The 
proportion of unreliable scans for LSM was 2.4%. The proportion of unreliable scans with operator 
experience in the top quartile (≥ 59 procedures) was significantly lower than lower three quarters 
combined (1.6% vs.4.7%, p=0.01 by Fisher’s Exact test).  The significant disagreement between first and 
second readings for LSM and CAP when obtained back to back was 18% and 11% respectively.   
Conclusion:  VCTE for estimation of LSM and CAP can be successfully deployed in a multicenter setting 
with low failure (3.2%) and high reliability (>95%) rates and high reproducibility. 
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Introduction 
Non-alcoholic fatty liver disease (NALFD) is a common cause of chronic liver disease and is 
estimated to occur in up to one-third of individuals in the United States.
1
 The clinical spectrum of NAFLD 
ranges from relatively benign non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH) 
that can progress to cirrhosis, liver failure or hepatocellular cancer.
2, 3
 In NAFL, only macrosteatosis is 
present on liver biopsy whereas, in NASH, macrosteatosis is present with a variable mix of hepatocyte 
ballooning and inflammation with or without fibrosis.
4, 5
 The distinction of different forms of NAFLD is 
important in the clinical management due to distinctly different prognosis.
6, 7
 Furthermore, fibrosis has 
emerged as the strongest predictor of long-term outcomes in patients with NAFLD.
8
 Liver biopsy has 
long been regarded as the gold standard for diagnosis and prognostication of patients with NAFLD.
9
 
However, histological interpretation of liver biopsy is subject to micro-inhomogeneity of liver tissue, 
sampling error based on length of liver biopsy core, presence of unfragmented core,  and observer 
variability among the pathologists.
10, 11
 Moreover, it requires the patient to undergo an invasive 
procedure that could be associated with discomfort and could rarely be associated with life threatening 
complications.
12-14
   
Liver stiffness measurement (LSM) assessed by vibration controlled transient elastography 
(VCTE) has been shown to be an easy to perform, non-invasive test to reliably estimate the degree of 
liver fibrosis in patients with NAFLD.
15-19
 VCTE measures the speed of a mechanically induced shear wave 
using pulse-echo ultrasonic acquisitions in a much larger portion of the tissue, approximately 100 times 
more than a liver biopsy core. However, prior studies evaluating the performance  of VCTE in NAFLD  
have been limited by medium (M+) size probe with ultrasound probe frequency of 3.5 MHz to measure 
LSM at a depth of 2.5 and 6.5 centimeters (cm) from the skin.
20, 21
 However, using M+ probe alone, the 
LSM was not reliable in subtanital number  of the patients with body mass index (BMI) as the major 
determinant for diagnostic errors in predicting fibrosis either by overestimating or underestimating the 
Page 4 of 26
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
  Vuppalanchi et al (5) 
 
stage of fibrosis.
22, 23
 The failure rate reported in these studies have been as high as 25%  presumably 
due to skin to liver capsule distance greater than 2.5 cm.
20, 21, 24
 Despite the failure rate, several studies 
reported correlation between stage of liver fibrosis and LSM value in patients with NAFLD.
20, 25-27
 The 
optimal cut-off values corresponding to various stages of fibrosis however have not been very apparent 
due to overlapping values of LSM across various stages. In a recent study from NASH CRN reported that 
LSM of 15.5 kPa had an AUROC of 0.93 for differentiating cirrhosis from non-cirrhosis stage of fibrosis 
with a specificity of 90%.
28
   
The newer version of VCTE available in the USA since early 2013, has several features that not 
only overcome its prior limitations but also enhances its role as a diagnostic tool in the evaluation of 
patients with NAFLD. First, it is approved  by the regulatory authorities to measure 3.5 MHz ultrasound 
coefficient of attenuation [CAP: Controlled Attenuation Parameter --the ultrasonic attenuation in the 
liver tissue depends on the viscosity (fat) of the medium (liver) and the distance of propagation of the 
ultrasonic signals into the liver].
29, 30
 While LSM is measured in kilo pascals (kPa), CAP is measured in 
decibels per meter (dB/m) and reflects the decrease in the amplitude of ultrasound signal in the liver.
30-
32
 Therefore, higher CAP is reflective of the higher degree of steatosis. CAP is displayed only when LSM is 
valid as it is only computed from the ultrasound signals used for acquiring LSM. The shear wave speed 
with estimation of stiffness and CAP currently allow for simultaneous assessment of both liver fibrosis 
and steatosis.
33, 34
 Several studies have also reported a good correlation between degree of hepatic 
steatosis or hepatic fat content by magnetic resonance imaging - proton density fat fraction.
35, 36
 Second, 
is the availability of extra-large (XL+) probe with an ultrasound frequency of 2.5 MHz for measurement 
of shear wave at skin to liver capsule depth of 3.5 and 7.5 cms. Lastly, the availability of an automatic 
probe selection software tool that determines the choice of the probe based on the skin liver capsule 
distance.  It is therefore possible that the failure rate of current VCTE may be much lower than the 
previous version in the evaluation of NAFLD.
23, 30, 37
  The aim of the current study is to report the success 
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and reliability of the newer, Fibroscan 502 Touch which offers a machine-derived choice between M+ 
and XL+ probe for simultaneous assessment of LSM and CAP in patients with NAFLD, particularly in a 
multicenter setting. Furthermore, a thorough understanding of factors that could potentially influence 
the LSM and CAP values is necessary.  
Methods 
 
Study design:  Individuals who are ≥ 18 years with histologically proven NAFLD and participating in the 
prospective NAFLD Database 2 study underwent simultaneous assessment for LSM and CAP using 
Fibroscan 502 Touch (Echosens™ North America 1050 Winter Street Waltham, MA 02451). The NAFLD 
Database 2 study was initiated by the NASH Clinical Research Network (NASH CRN) in December 2009 
and its inclusion and exclusion criteria are similar to the previously reported NASH CRN Database study 
except that all participants required histologically confirmed NAFLD for eligibility.
38
  Eligible participants 
were enrolled into the NASH CRN Database study at eight medical centers across the United States: Case 
Western Reserve (Cleveland, OH); Duke University (Durham, NC); Indiana University (Indianapolis, IN); 
Saint Louis University (St. Louis, MO); University of California, San Diego (San Diego, CA); University of 
California, San Francisco (San Francisco, CA); Virginia Mason Medical Center and Swedish Medical Center 
(Seattle, WA); and Virginia Commonwealth University (Richmond, VA). The data were stored, monitored, 
and analyzed at the Data Coordinating Center at the Johns Hopkins Bloomberg School of Public Health.
38
 
This study (NCT01030484) was approved by the Institutional Review Boards of the respective 
participating institutions and all participants provided written informed consent prior to enrollment. No 
employees of Echosens were investigators in this study, or controlled the acquisiiton, analysis, 
interpretation, or reporting of results.  
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Study Visit and Procedures: All participants presented for an outpatient study visit after 12 hours of 
fasting to the respective clinical research centers after overnight fast and were evaluated by the study 
nurse and the clinical investigator. Participants underwent anthropometric measurements and 
completed study-specific questionnaires, physical examination, and blood tests. Routine laboratory 
studies were performed on fresh samples in Clinical Laboratory Improvement Amendments (CLIA) 
certified laboratories at each clinical site according to standard clinical protocols.
38
   
 
Equipment and Technician expertise: Fibroscan® 502 Touch with two probes - Medium (M+) and Extra-
large (XL+) was available at each of the participating medical centers for measuring LSM and CAP. The 
type of probe required for each participant was based on the automatic probe selection tool embedded 
within the Fibroscan® 502 Touch operating software.  These machines were provided by the Echosens 
company to adult clinical centers of the NASH CRN through a clinical trials agreement between the 
Echosens and the NIDDK.  
 
All studies were performed by a dedicated study coordinator at each site using a standardized 
protocol.
38
 All study coordinators were new to the Fibroscan technology and underwent standardized 
training (didactic followed by hands-on testing in 5 participants under the supervision of a proctor) by 
Echosens North America and were certified before conducting VCTEs for the current study. Each patient 
was placed supine with right arm raised behind his/her head and remained still during the procedure.  
With probe over the liver region, readings were attempted until ten valid measurements were obtained. 
All studies were started with an M+ probe with XL+ probe as rescue only when prompted by the 
automatic probe selection tool. In rare instances, where the machine’s recommendation fluctuated 
between M+ and XL+ probes, the study coordinator was instructed to choose the XL+ probe. Two scans 
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were performed during the same visit several minutes apart by the same coordinator (intra-operator 
assessment) or by a second coordinator (inter-operator assessment) in a subset of participants. 
 
Statistical Analysis 
 
Demographics, anthropometrics, liver tests, serum chemistries, histologic characteristics and Fibroscan 
metrics were compared between M+ and XL+ probe types using chi-square tests for categorical variables 
and t-tests for continuous variables. Both means with standard deviations and medians with 
interquartile were presented for Fibroscan data due to possible non-normality of the distribution. 
Correlation between 1
st
 and 2
nd
 readings used Spearman correlation coefficient and Fisher’s z-
transformation.  
The unreliability of LSM values was defined as IQR/Median > 30%. Significant disagreement 
between 1
st
 and 2
nd
 readings was defined as absolute value of the difference > 95% limits of agreement 
between the 2 readings i.e., using linear regression, the difference between the 2 readings of LSM and 
CAP was not related to the mean of the 2 readings. This was further visualized using Bland-Altman plots. 
The B&A plot analysis is a simple way to evaluate a bias between the mean differences, and to estimate 
an agreement interval, within which 95% of the differences of the second method, compared to the first 
one, fall. It simply quantifies the bias and a range of agreement, within which 95% of the differences 
between one measurement and the other are included. It is also possible to say that the bias is 
significant, when the line of equality is not within the confidence interval of the mean difference.  For 
analyses of LSM and CAP, the mean of the two readings or first reading if second reading was missing 
was used; observations with missing data for the second reading (n=28 for LSM; n=24 for CAP) were 
excluded from selected analyses of inter-and intra-observer  differences of LSM and CAP.  The CAP data 
for 183 patients were missing due to computer software problem using XL+ probe at the start of 
FibroScan assessments.  
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Multiple logistic regression with Akaike’s Information Criterion (AIC) was used to assess associations for 
the binary outcomes of unreliability and significant disagreement from a candidate set including age, 
gender, ethnicity, race, body mass index, waist circumference, LSM (or CAP), INR, ALT, AST, serum 
bilirubin, serum alkaline phosphatase, blood platelet count, steatosis score, fibrosis stage, NASH 
diagnosis, time from biopsy, probe type, and same or different operator. Robust multiple linear 
regression was used to test for differences by probe type in LSM adjusted for fibrosis stage and BMI, and 
CAP adjusted for steatosis score and BMI.
39
 LSM was modeled both untransformed and log transformed 
due to non-normality of the distribution. All analyses were conducted using SAS (Version 9.3 of the SAS 
System for Windows, Cary, NC: SAS Institute Inc., 2002-2004) and Stata (StataCorp. 2015. Stata 
Statistical Software: Release 14. College Station, TX: StataCorp LP). 
 
Results 
 
Study Population 
Nine hundred and ninety two individuals who underwent evaluation with VCTE as part of the NAFLD 
Database 2 Study between April 2014 and May 2016 were included in this analysis.  Of them, 961 
participants had two VCTE examinations back to back, with second VCTE procedure by the same 
operator in 838 patients and by a different operator in 123 patients.  Total number of LSM and CAP 
available for analysis were 1641 and 1475 respectively.  
The selected clinical, laboratory, and histological features of our study cohort are described in Table 1. 
Overall, the mean age was 51 years with 65% women and the cohort is predominantly Caucasian (84% 
with 10% Hispanic ethnicity).  The mean BMI was 33.6 ± 6.5 kg/m
2
 with 31% belonging to 
normal/overweight and obese categories each and the remaining 36% belonged to extreme obese 
category (Table 1).  The study cohort consisted predominantly of NASH patients with 54% showing 
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definite NASH and 19% exhibiting borderline NASH. The mean duration between liver biopsy and VCTE 
was 2.6 years.  Histograms of LSM (Figure 1, panel a) and CAP (Figure 1, panel b) showed a right-skewed 
distribution for LSM and a normal distribution for CAP. 
VCTE Failure Rate  
The failure rate for VCTE for obtaining LSM and CAP was 3.2% (55/1696) based on the total number of 
scans performed in the current study.  The failure rate based on the total number of patients included in 
this study was slightly higher at 5.5% (55/992). The 3 most frequent reasons for failure: inability to 
obtain a scan due to excess skin to liver capsule distance (n=19); machine/technician error (n=13); and 
patient refusal (n=11). Other reasons included invalid readings (n=6), intolerable pain (n=4) and 
undetectable liver (n=1).  
Performance Characteristics  
Both median LSM and median CAP values were significantly higher in the higher BMI categories (Table 
2). The use of XL+ probe was significantly greater in higher BMI categories, i.e., 27% in 
normal/overweight, 61% in obese, and 87% in extreme obese patients (p<0.001). The mean difference 
between the 1
st
 and 2
nd
 readings of LSM was 0.0 ± 5.5 kPa and did not significantly differ among 
different BMI categories (Table 2). The mean difference between the 1
st
 and 2
nd
 CAP readings was 2 ± 36 
dB/m and it was also not significantly different among various BMI categories (Table 2). The Bland-
Altman plot to describe the agreement between the two LSM readings showed that 95% of the 
difference between the 1
st
 and 2
nd
 readings occurred within  ± 2.9 kPa with no bias over the range of 
values (4-75 kPa) (Figure 1, panel c). Similarly, the Bland-Altman plot to describe the agreement 
between the two CAP readings showed that 95% of the difference between the 1
st
 and 2
nd
 readings 
occurred within  ±51 dB/m with no bias over the range of values (100-400 dB/m) (Figure 1, panel d). 
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Factors associated with Unreliable LSM  
 
Unreliable results due to significant variability i.e., median LSM values with IQR/median >30% were 
found in 2.4% (39/1651) of VCTE scans. The relationship between operator experience in quartiles and 
proportion of unreliable scans was first examined (Table 3).  The proportion of unreliable scans in the 4
th
 
quartile was 1.6% and was significantly lower than first three quarters combined (4.7%, p=0.01 by 
Fisher’s Exact test). Logistic regression model with all variables from Table 1 using AIC criteria showed 
that BMI category (OR: 2.7, 95% CI: 1.5, 4.8; p=0.001) and Hispanic ethnicity (OR: 3.2, 95% CI: 1.1, 9.3; 
p=0.03) were associated with higher odds of unreliable LSM (Table 4). On the other hand lower values of 
international normalized ratio (INR) (OR: 0.94 per %, 95% CI: 0.89, 0.99; p=0.01) and ALT (OR: 0.91 per 
10 U/L, 95% CI: 0.78, 1.05; p=0.19) were associated with decreased odds of unreliable LSM values (Table 
4). There was a 25% decrease in the odds of unreliability per increasing quartile of prior exams adjusted 
for other confounders (OR: 0.75, 95% CI: 0.52, 1.08; p=0.12) (Table 4).  
 
Factors Associated with Significant Disagreement between 1
st
 and 2
nd
 VCTE Readings  
Values of LSM and CAP between 1
st
 and 2
nd
 exams were compared, and significant disagreement was 
defined as absolute value of the difference > 95% limits of agreement between the 2 readings. Using 
linear regression, the difference between the 2 readings of LSM and CAP was not related to the mean of 
the 2 readings (Change in LS difference / 1 unit increase in LS mean = 0.002 kPa (SE=0.016); Change in 
CAP difference / 1 unit increase in CAP mean = -0.001 dB/m (SE=0.024). This can also be visually seen in 
the Bland-Altman plots in Figures 1c and 1d. The rate of significant disagreement for LSM was 18% (169 
out of 964 paired LSM measurements) while the rate of significant disagreement for CAP was 11% (85 
out of 785 paired CAP measurements).  The factors associated with significant disagreement between 1
st
 
and 2
nd
 measurements of LSM and CAP are shown in Table 5.  While the significant disagreement 
between two LSM values increased with increasing LSM score (OR: 1.06, 95% CI: 1.04, 1.09; p<0.001), 
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higher fibrosis stage (OR: 1.22, 95% CI: 1.02, 1.46; p=0.03), and AST (OR: 1.07, 95% CI: 1.01, 1.13; 
p=0.03), factors such as male gender (OR:0.52, 95% CI: 0.32, 0.86; p=0.01), White race (OR: 0.50, 95% CI: 
0.26, 0.96, p=0.04) and platelet count (OR: 0.96, 95% CI: 0.93, 1.00; p=0.04) were associated with lower 
significant disagreement. Factors associated with less disagreement between 1
st
 and 2
nd
 CAP scores 
were higher CAP (per every 10 dB/m) values (OR: 0.91, 95% CI: 0.86, 0.96; p=0.001) and steatosis grade 
(OR: 0.67, 95% CI: 0.49, 0.92; p=0.01). Waist circumference was associated with higher disagreement in 
both CAP (OR: 1.03, 95% CI: 1.01, 1.05, p=0.006) and LSM (OR: 1.02, 95% CI: 1.00, 1.04; p=0.09) (Table 
5).  
 
The correlation between 1
st
 and 2
nd
 measurements obtained by the same coordinator (intra-observer) 
and by a different coordinator (inter-observer) was assessed in 838 and 123 participants, respectively. 
The correlation between 1
st
 and 2
nd 
readings was high for both inter- (r=0.84) and intra-operator (r=0.90) 
LSM values. This correlation was significantly higher when M+ probe was used as compared to XL+ 
probe (inter-operator r=0.90 vs. 0.77, p=0.02; intra-operator r=0.94 vs. 0.87; p<0.001). The correlation 
between the 1
st
 and 2
nd
 CAP readings was high for both inter- (r=0.70) and intra- (r=0.82) operator 
values. The inter-operator correlation did not differ by M+ vs. XL+ probe type (r=0.64 vs 0.68; p=0.71) 
but the intra-operator correlation was significantly higher using M+ vs. XL+ probe (r=0.85 vs. 0.75, 
p=0.0003). 
 
Probe Size and Performance Characteristics 
The mean and median LSM values with the XL+ probe were significantly higher than with the M+ probe 
(mean ± SD  12.5±13.1 vs. 9.7±8.8 kPa, p<0.0001; median[IQR] = 7.9[5.7, 13.6] vs. 6.8[4.9, 10.8] kPa, 
p<0.0001). However, when adjusted for BMI and fibrosis stage, mean LSM using M+ probe was 
significantly higher by 0.8 kPa (95% CI: 0.3,1.4; p=0.003) compared to XL+ probe and the ratio of LSM 
using M+ / XL+ was significantly higher by 6% (95% CI=3%, 9%; p<0.001) (back-transforming log LSM) 
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(Table 6). The mean CAP score in XL+ probe group was significantly higher than the M+ probe group 
(326±47 vs. 288±52 dB/m, p<0.0001) (Table 2). When adjusted for BMI and severity of hepatic steatosis 
by histology, CAP scores obtained using XL+ probe were higher by 16 dB/m (95% CI: 8, 24; p <0.001) 
(Table 6).   
Discussion 
The VCTE examination offers an opportunity to noninvasively assess the extent of liver fibrosis 
and hepatic steatosis in patients with NAFLD in an outpatient clinic setting.  Moreover, the change in 
LSM and CAP values over time may provide an opportunity to monitor disease progression without a 
liver biopsy.  Soon after its approval in 2013, there has been interest in incorporating VCTE into 
ambulatory gastroenterology and hepatology practices throughout North America.  However, the 
performance of VCTE via Fibroscan®502 Touch which offers two probes and an automated probe 
selection by the device is not well understood.   
The main findings from this study are (a) failure rate for obtaining valid LSM and CAP using 
currently available VCTE device and software technology is quite minimal; (b) unreliable liver stiffness 
measurements are rare but are associated with obesity and operator inexperience; and (c) 
reproducibility of liver stiffness and CAP measurements is high whether the test is repeated by the 
same, or by another operator.   
In a recent study conducted in the United States by Tapper et al., VCTE was performed in 164 
patients with NAFLD utilizing an M+ probe and it reported 73% success rate for obtaining reliable LSM 
which was defined as 10 valid measurements and IQR ≤ 30% of the median.  If we apply the same 
definition as Tapper et al., the success rate for VCTE in our experience was high at 94%. We believe the 
improved performance of the VCTE in our study is due to the availability of the XL+ probe which was 
utilized in 60% of the participants. In the study by Tapper et al. extreme obesity was strongly associated 
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with uninterpretable VCTE results when obtained with an M+ probe (OR: 8.76; 95% CI 3.82-21.0). In our 
study, nearly 90% of the extremely obese participants had their VCTE performed with an XL+ probe and 
thus overcoming the limitation of the M+ probe in obtaining valid reading in those with extreme obesity. 
Finally, Hispanic ethnicity was associated with unreliable LSM in the current cohort. We suspect that this 
association may be related to greater prevalence of abdominal adiposity, shorter height and possibly 
smaller intercostal space.    
The divergent relationship between the LSM and CAP values with the size of the probe is 
interesting. Although caution should be exercised in interpreting these findings since these values are 
not obtained using both probes in the same patient, the current study revealed that LSM values with XL+ 
probe are lower by 0.8 kPa while CAP values are increased by approximately 16 dB/m.  Although the 
lower LSM values by the XL+ probe, when compared to M+ probe in the same individual, has been 
described before,
40
 a higher CAP values with the XL+ probe for similar degree for steatosis is a novel 
finding.  These results are important when interpreting the changes in the values of LSM and CAP during 
the course a longitudinal study when the size of the probe may inadvertently change.  Therefore, 
consideration should be given for ± 1 kPa and ± 16 kPa when establishing a threshold cut-off for the 
stage of fibrosis and degree of steatosis respectively.   
 An important shortcoming of this study is that it did not examine the relationship between LSM 
and CAP and liver histology because the mean duration between liver biopsy and VCTE was 2.6 years. 
We believe that it is best to investigate the relationship between VCTE and liver histology obtained at a 
much closer interval.  In an earlier study from the NASH CRN, the relationship between serum keratin 18 
fragments and liver histology was much stronger when they were measured in close proximity to the 
liver biopsy.
41
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In summary, VCTE for estimation of LSM and CAP can be successfully deployed in a multi-center 
setting with a very low failure rate (<2.5%) and high reliability rate (>95%). Although the reasons for 
failure and unreliable scans appear to be related to factors associated with the patient, VCTE 
technology, or the operator, the current study suggests that with sufficient operator experience, it is 
possible to minimize failure and unreliability rates.  Our study demonstrates high performance 
characteristics for currently available VCTE, supporting its use in clinical practice and in multicenter 
research setting.  
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Figure legend 
Figure 1.  Histogram of (a) Liver Stiffness Measurement (LSM); (b) Controlled Attenuation Parameter 
(CAP); (c) Bland-Altman plot of the difference in the 1
st
 and 2
nd
 reading of LSM values against the mean 
of the two measurements. The limits of agreement are indicated by the red lines—that is, the interval of 
1.96 * standard deviation of the measurement differences. 95% of the difference between the 1
st
 and 
2
nd
 readings occurred within ± 2.9 kPa with no bias over the range of values (4-75 kPa); (d) Bland-Altman 
plot of the difference in the 1
st
 and 2
nd
 reading of CAP values against the mean of the two 
measurements. 95% of the differences between the 1
st
 and 2
nd
 CAP readings occurred within ± 51 dB/m 
with no bias over the range of values (100-400 dB/m). 
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Table 1. Selected demographic, histologic, and VTCE features by BMI category at the closest visit to 
VCTE evaluation. All values are mentioned in means (SD) unless otherwise specified. 
 BMI category   
 Normal / 
Overweight* 
<30 kg/m
2
 
(n=311) 
Obese 
30-34.9 kg/m
2
 
(n=311) 
Extreme Obese 
≥35 kg/m
2
 
(n=358) 
Total† 
(n=992) 
P-value 
Demographics      
 Age, Years 53.5 (12.2) 51.5 (11.9) 49.6 (12.1) 51.4 (12.2)  
 Gender - % Male 40.5 35.3 30.6 35.4 0.03 
 Race     <0.001 
  % White 81.6 82.1 87.1 84.1  
  % Black 1.3 4.6 3.9 3.0  
  % Asian 11.5 5.8 1.1 5.8  
  % Other / refused 5.6 7.5 7.9 7.0  
 Ethnicity - % Hispanic 12.1 10.7 7.9 10.2 0.18 
Anthropometrics      
 Waist circumference – cm  94 (8) 105 (8) 120 (11) 107 (14) <0.001 
 Body mass index – kg/m
2
 27.0 (2.3) 32.3 (1.4) 40.6 (4.7) 33.6 (6.5) <0.001 
Liver tests      
 AST – U/L 39 (27) 42 (32) 45 (32) 42 (31)  
 ALT – U/L 47 (36) 52 (41) 55 (42) 52 (40)  
 Alkaline phosphatase – U/L 74 (29) 80 (30) 84 (33) 79 (31)  
 Total bilirubin – mg/dL 0.8 (0.4) 0.7 (0.6) 0.7 (0.6) 0.7 (0.6)  
 Serum chemistries      
 Platelet count – 1K cells / uL 215 (62) 227 (73) 224 (74) 222 (70)  
 International normalized ratio 1.05 (0.16) 1.04 (0.16) 1.07 (0.23) 1.05 (0.18)  
Histology at closest visit      
 Sample size 288 288 342 893  
 Years from biopsy 2.7 (2.8) 2.3 (2.6) 2.3 (2.6) 2.6 (2.6)  
 NASH diagnosis     <0.001 
  No NAFLD - % 3.5 8.0 2.0 4.2  
  NAFLD, no NASH - % 32.6 18.3 21.0 23.3  
  Borderline - % 19.4 21.4 17.2 18.9  
  Definite - % 44.4 52.2 59.8 53.6  
 Fibrosis     0.01 
  None - % 32.3 26.0 21.6 25.9  
  Stage 1 – mild - % 27.4 27.4 23.7 25.9  
  Stage 2 – moderate - % 16.0 12.8 18.4 16.4  
  Stage 3 – bridging - % 16.0 24.0 26.3 22.5  
  Stage 4 – cirrhosis - % 8.3 9.7 9.9 9.4  
  Mean stage 1.4 (1.3) 1.6 (1.3) 1.8 (1.3)   
 Steatosis     0.27 
  Grade 0 - % 9.3 10.0 5.2 7.9  
  Grade 1 - % 42.2 38.1 44.9 42.5  
  Grade 2 - % 28.4 31.5 29.4 29.5  
  Grade 3 - % 20.1 20.4 20.4 20.1  
  Mean grade 1.6 (0.9) 1.6 (0.9) 1.7 (0.9)   
*55 normal pa;ents + 256 overweight pa;ents; †12 pa;ents with missing BMI data are included in the total 
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Table 2. Performance characteristics of the VCTE in various categories of BMI. 
 
 BMI category 
 Normal / 
Overweight* 
<30 kg/m
2
 
(n=311) 
Obese 
30-34.9 kg/m
2
 
(n=311) 
Extreme Obese 
≥35 kg/m
2
 
(n=358) 
Total† 
(n=992) 
P-value 
      
 Probe type - % XL probe 26.7% 60.8% 87.4% 59.7% <0.001 
      
Liver stiffness measurement      
  Average 1
st
 and 2
nd
 reading       
    Mean (SD) - kPa 9.0 (9.6) 11.0 (11.8) 13.8 (12.8) 11.4 (11.7) <0.001 
    Median [IQR] - kPa 6.0 [4.4, 9.3] 7.1 [5.2, 11.8] 9.3 [6.6, 15.0] 7.5 [5.3, 12.2]  
  Difference 1
st
 and 2
nd
 reading      
    Mean (SD) - kPa -0.2 (4.8) 0.3 (6.3) 0.0 (5.2) 0.0 (5.5) 0.96 
    Median [IQR] – kPa 0.0 [-0.7, 0.7] 0.0 [-0.7, 1.1] 0.1 [-1.3, 1.4] 0.0 [-0.9, 1.1]  
    95% limits of agreement† - kPa      
 Inter-reader (n=123) ±3.0 ±3.3 ±3.5 ±3.6  
 Intra-reader (n=838) ±2.0 ±2.5 ±4.1 ±2.8  
 Total (n=964) ±2.0 ±2.6 ±3.9 ±2.9  
      
Controlled Attenuation Parameter 
(CAP) 
     
  Average 1
st
 and 2
nd
 reading       
    Mean (SD) – dB/m 284 (56) 303 (47) 336 (42) 307 (53) <0.001 
    Median [IQR] – dB/m 284 [254, 321] 306 [270, 337] 340 [311, 366] 312 [272, 347]  
  Difference 1
st
 and 2
nd
 reading      
    Mean (SD) – dB/m 3 (32) -2 (38) 5 (36) 2 (36) 0.07 
    Median [IQR] – dB/m 3 [-14, 18] -3 [-21, 16] 0 [-16, 24] 0 [-16, 19]  
    95% limits of agreement† - dB/m      
 Inter-reader (n=114) ±52 ±77 ±70 ±64  
 Intra-reader (n=669) ±45 ±49 ±57 ±49  
 Total (n=785) ±46 ±54 ±58 ±51  
*55 normal par;cipants + 256 overweight par;cipants; †12 pa;ents with missing BMI data are included in the total 
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Table 3:  Proportion of operator’s experience as quartiles and Unreliable VCTE scans 
   Unreliable exams 
Quartile No. prior exams Total exams No.  % 
1 1 to 11 244 11 4.9 
2 12 to 27 250 10 4.1 
3 28 to 58 245 14 5.0 
4 59 to 180 253 4 1.6 
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Table 4. Covariates of unreliable liver stiffness measurement*  
 Odds of unreliable liver stiffness measurement 
Covariate Odds Ratio 95% CI P value 
Body Mass Index (per category†)  2.7 1.5, 4.8 0.001 
International normalized ratio (%) 0.94 0.89, 0.99 0.01 
Ethnicity (Hispanic vs non-Hispanic) 3.2 1.1, 9.3 0.03 
Age (per yr) 1.03 1.00, 1.07 0.08 
Prior operator-specific readings (per quartile) 0.75 0.52, 1.08 0.12 
ALT (per 10 U/L) 0.91 0.78, 1.05 0.19 
    
*Unreliable liver stiffness defined as IQR/median > 30%. Overall rate of unreliable liver stiffness was 2.4% (39/1651).  
Covariates were selected using AIC criteria from a multiple logistic model regressing unreliable liver stiffness measurement on 
candidate set of age, gender, ethnicity, race, BMI, waist circumference, mean and difference between 1
st
 and 2
nd
 readings of 
liver stiffness, INR, ALT, AST, bilirubin, alkaline phosphatase, platelet count, steatosis score, fibrosis stage, NASH diagnosis, time 
from biopsy, and same or different operator, prior operator-specific readings in NASHCRN patients 
†BMI categorized as 1=normal/overweight; 2=obese; 3=very obese 
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Table 5. Factors associated with significant disagreement* between 1
st
 and 2
nd
 readings 
 Odds of significant disagreement* 
 OR 95% CI P-value 
LSM†    
  LSM (kPa) 1.06 1.04, 1.09 <0.001 
  Gender (male vs. female) 0.52 0.32, 0.86 0.01 
  Fibrosis (stage) 1.22 1.02, 1.46 0.03 
  AST (10 U/L) 1.07 1.01, 1.13 0.03 
  Race (white vs. non-white) 0.50 0.26, 0.96 0.04 
  Platelet count (10K cells/uL) 0.96 0.93, 1.00 0.04 
  Alkaline phosphatase (10 U/L) 0.99 0.98, 1.00 0.06 
  Operator (same vs different) 0.59 0.33, 1.06 0.08 
  Steatosis (score) 0.81 0.64, 1.02 0.08 
  Waist circumference (cm) 1.02 1.00, 1.04 0.09 
  Ethnicity (Hispanic vs. not Hispanic) 0.53 0.24, 1.21 0.13 
  Body mass index (/ category) 1.15 0.78, 1.70 0.47 
    
 CAP‡    
  CAP ( per 10 dB/m) 0.91 0.86, 0.96 0.001 
  Waist circumference (cm) 1.03 1.01, 1.05 0.006 
  Steatosis (grade) 0.67 0.49, 0.92 0.01 
  International normalized ratio (%) 1.01 1.00, 1.02 0.04 
  Age (years) 0.98 0.96, 1.00 0.05 
  Race (white vs. non-white) 0.50 0.25, 1.00 0.05 
*Defined as absolute value of the difference > 95% limits of agreement between the 2 readings; Predictors were selected using 
AIC criteria from a multiple logistic model regressing significant disagreement on candidate set of age, gender, ethnicity, race, 
BMI category, waist circumference, INR, ALT, AST, bilirubin, alkaline phosphatase, platelet count, steatosis score, fibrosis stage, 
NASH diagnosis, time from biopsy, and operator 
†rate of signiﬁcant disagreement is 18% (169/964) 
‡rate of signiﬁcant disagreement is 11% (85/785) 
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Table 6.  Relationship between probe type and liver stiffness and CAP measurements, adjusted for the 
body mass index  
 XL+ probe M+ probe BMI-Adjusted 
Difference (XL – M) 
 N BMI-
Adjusted 
Mean 
N BMI-
Adjusted 
Mean 
Mean 95% CI P-value 
Liver stiffness (kPa)        
Fibrosis stage        
 0 132 5.4 112 6.5 -1.0 -1.6, -0.5 <0.001 
 1 136 6.4 106 7.2 -0.9 -1.7, -0.1 0.03 
 2 90 7.2 57 7.8 -0.5 -1.7, 0.6 0.35 
 3 137 11.3 70 13.7 -2.4 -4.6, -0.2 0.04 
 4 57 21.3 30 26.2 -4.8 -12.6, 2.9 0.22 
 Total 552 8.0 375 8.8 -0.8 -1.4, -0.3 0.003 
        
CAP (dB/m)        
Steatosis score        
 0 20 268 41 289 -21 -50, 9 0.17 
 1 160 313 155 300 13 0, 25 0.05 
 2 117 321 106 306 15 1, 29 0.04 
 3 80 342 73 310 32 18, 46 <0.001 
 Total 377 319 375 303 16 8, 24 <0.001 
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